NASDAQ:VSTM - Verastem Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started $5.69 -0.16 (-2.74 %) (As of 10/19/2018 04:00 PM ET)Previous Close$5.69Today's Range$5.67 - $6.0152-Week Range$2.77 - $10.35Volume2.38 million shsAverage Volume4.72 million shsMarket Capitalization$430.52 millionP/E Ratio-3.23Dividend YieldN/ABeta2.75 Company ProfileDiscussionAnalyst RatingsChartEarnings HistoryFinancialsInsider TradesHeadlinesOptions ChainSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Verastem, Inc., a biopharmaceutical company, focuses on developing and commercializing drugs for the treatment of cancer. Its programs target the focal adhesion kinase (FAK) and the phosphoinositide 3-kinase (PI3K) signaling pathways. The company's lead FAK inhibitor is defactinib, an orally available candidate for combination therapy with immuno-oncology agents and other anti-cancer compounds. Its defactinib is in Phase 1b study for the treatment of pancreatic cancer, as well as in Phase 1/2 clinical trial for the treatment of ovarian cancer, non-small cell lung cancer, mesothelioma, and pancreatic cancer. The company also engages in developing duvelisib, an investigational oral therapy that targets the PI3K signaling pathway, as well as attacks malignant B-cells and T-cells and disrupt the tumor microenvironment to help thwart their growth and proliferation for patients with hematologic cancers through the dual inhibition of PI3K delta and gamma. Its duvelisib is in Phase 3 randomized and late-and mid-stage clinical trials for the treatment of patients with relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma, as well as completed the Phase 2 study for the treatment of patients with double-refractory indolent non-Hodgkin lymphoma. The company has license agreements with Infinity Pharmaceuticals, Inc.; and Pfizer, Inc. Verastem, Inc. was founded in 2010 and is headquartered in Needham, Massachusetts. Receive VSTM News and Ratings via Email Sign-up to receive the latest news and ratings for VSTM and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryBiotechnology SectorMedical SymbolNASDAQ:VSTM CUSIP92337C10 Webwww.verastem.com Phone781-292-4200 Debt Debt-to-Equity Ratio0.19 Current Ratio7.70 Quick Ratio7.70 Price-To-Earnings Trailing P/E Ratio-3.23 Forward P/E Ratio-3.47 P/E GrowthN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / CashN/A Book Value$1.19 per share Price / Book4.78 Profitability EPS (Most Recent Fiscal Year)($1.76) Net Income$-67,800,000.00 Net MarginsN/A Return on Equity-122.36% Return on Assets-81.96% Miscellaneous Employees69 Outstanding Shares73,590,000Market Cap$430.52 million Verastem (NASDAQ:VSTM) Frequently Asked Questions What is Verastem's stock symbol? Verastem trades on the NASDAQ under the ticker symbol "VSTM." How were Verastem's earnings last quarter? Verastem Inc (NASDAQ:VSTM) posted its quarterly earnings results on Wednesday, August, 8th. The biopharmaceutical company reported ($0.30) earnings per share for the quarter, topping the consensus estimate of ($0.33) by $0.03. The biopharmaceutical company earned $10 million during the quarter. View Verastem's Earnings History. When is Verastem's next earnings date? Verastem is scheduled to release their next quarterly earnings announcement on Tuesday, November 6th 2018. View Earnings Estimates for Verastem. What price target have analysts set for VSTM? 9 Wall Street analysts have issued 12-month target prices for Verastem's shares. Their predictions range from $12.00 to $17.00. On average, they expect Verastem's share price to reach $15.00 in the next year. This suggests a possible upside of 163.6% from the stock's current price. View Analyst Price Targets for Verastem. What is the consensus analysts' recommendation for Verastem? 9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Verastem in the last year. There are currently 9 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Verastem. What are Wall Street analysts saying about Verastem stock? Here are some recent quotes from research analysts about Verastem stock: 1. Cann analysts commented, "Verastem’s loss per share of $0.30 was in line with our estimated $0.30. There was an unanticipated upfront payment from Yakult of $10 million, in association with a collaboration agreement. This was offset by higher than estimated operating expense. SG&A of $15.8 million was higher than our estimated $90.0 million due to infrastructure ramp in association with the anticipated launch of Duvelisib in Q4 2018. R&D of $12.4 million exceeded our estimated $10.6 million due to further development of Duvelisib." (8/9/2018) 2. According to Zacks Investment Research, "Verastem, Inc., a clinical stage biopharmaceutical company, focuses on discovering and developing drugs to improve outcomes for patients with cancer. Its programs target the focal adhesion kinase (FAK) and the phosphoinositide 3-kinase (PI3K)/mTOR signaling pathways. Its lead FAK inhibitor is defactinib (VS-6063), an orally available candidate for combination therapy with immuno-oncology agents and other anti-cancer compounds. The company's defactinib is in Phase 1b study for the treatment of pancreatic cancer, as well as in Phase 1/2 clinical trial for the treatment of ovarian cancer, non-small cell lung cancer, mesothelioma, and pancreatic cancer. It also engages in developing duvelisib, an investigational oral therapy that targets the PI3K signaling pathway, as well as attacks malignant B-cells and T-cells and disrupt the tumor microenvironment to help thwart their growth and proliferation for patients with lymphatic cancers through the dual inhibition of PI3K delta and gamma. " (7/20/2018) 3. HC Wainwright analysts commented, "Olga Smolentseva, Ph.D. – (646-975-6966) / [email protected] Our Takeaways From Verastem Investor Day; Reiterate Buy We anticipate duvelisib approval in 4Q18. On May 2, Verastem Oncology held an Analyst and Investor Day in New York and provided an overview on duvelisib’s development and management’s plans for the drug’s commercial launch. Recall, on February 7, Verastem filed a NDA application for duvelisib, the company’s dual PI3K-γ/δ inhibitor, for the treatment of relapsed/refractory chronic lymphocytic leukemia and small lymphocytic lymphoma (r/r CLL/ SLL). The company has also filed for an accelerated approval of duvelisib for the treatment of follicular lymphoma (FL). We note that the FDA has granted a priority review for the duvelisib application, with the PDUFA date scheduled for October 5." (5/3/2018) 4. Cantor Fitzgerald analysts commented, "Working off Overhangs. We think VSTM shares are undervalued relative to the duvelisib opportunity, and this is partly a function, in our view, of overhangs, particularly cash. VSTM had just under $87 mln in cash, which is sufficient to fund the company into 2H18, but will need additional capital to see duvelisib through commercialization. VSTM has an additional $35 mln available under a debt facility, and the company could add additional cash through a partner deal. It has been our anticipation that VSTM will need to address the capital markets in some way in 2018." (3/13/2018) Are investors shorting Verastem? Verastem saw a increase in short interest in the month of September. As of September 28th, there was short interest totalling 14,621,952 shares, an increase of 81.3% from the September 14th total of 8,066,813 shares. Based on an average daily volume of 5,706,177 shares, the short-interest ratio is currently 2.6 days. Currently, 20.3% of the shares of the company are short sold. View Verastem's Current Options Chain. Who are some of Verastem's key competitors? Some companies that are related to Verastem include Puma Biotechnology (PBYI), Endocyte (ECYT), Aimmune Therapeutics (AIMT), Theravance Biopharma (TBPH), Clovis Oncology (CLVS), Innoviva (INVA), G1 Therapeutics (GTHX), Enanta Pharmaceuticals (ENTA), ARMO Biosciences (ARMO), Portola Pharmaceuticals (PTLA), Zogenix (ZGNX), Corcept Therapeutics (CORT), Biohaven Pharmaceutical (BHVN), Wave Life Sciences (WVE) and Spectrum Pharmaceuticals (SPPI). Who are Verastem's key executives? Verastem's management team includes the folowing people: Mr. Robert Forrester, Pres, CEO & Director (Age 54)Dr. NgocDiep T Le M.D., Ph.D., Chief Medical Officer (Age 50)Mr. Richard H. Aldrich, Founder and Consultant (Age 64)Dr. Robert A. Weinberg, Co-Founder and Chair of Scientific Advisory BoardDr. Piyush B. Gupta, Co-Founder How do I buy shares of Verastem? Shares of VSTM can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is Verastem's stock price today? One share of VSTM stock can currently be purchased for approximately $5.69. How big of a company is Verastem? Verastem has a market capitalization of $430.52 million. The biopharmaceutical company earns $-67,800,000.00 in net income (profit) each year or ($1.76) on an earnings per share basis. Verastem employs 69 workers across the globe. What is Verastem's official website? The official website for Verastem is http://www.verastem.com. How can I contact Verastem? Verastem's mailing address is 117 KENDRICK STREET SUITE 500, NEEDHAM MA, 02494. The biopharmaceutical company can be reached via phone at 781-292-4200 or via email at [email protected] MarketBeat Community Rating for Verastem (NASDAQ VSTM)Community Ranking: 3.1 out of 5 ( )Outperform Votes: 354 (Vote Outperform)Underperform Votes: 224 (Vote Underperform)Total Votes: 578MarketBeat's community ratings are surveys of what our community members think about Verastem and other stocks. Vote "Outperform" if you believe VSTM will outperform the S&P 500 over the long term. Vote "Underperform" if you believe VSTM will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 10/20/2018 by MarketBeat.com StaffFeatured Article: How do investors use RSI to grade stocks?